Jeannie Kim's questions to Stoke Therapeutics Inc (STOK) leadership • Q2 2025
Question
Jeannie Kim, on behalf of Tom Schroeder from BTIG, asked about the rationale for advancing STK-002 into clinical development for ADOA at this time and requested details on the key non-human primate (NHP) data that supported the decision.
Answer
Interim CEO Ian Smith stated the decision was triggered by compelling NHP data showing potential vision improvement. CMO Barry Ticho elaborated that in a naturally occurring monkey model of ADOA, STK-002 demonstrated improvements in both mitochondrial function (measured by FPF) and optic nerve function (measured by ERG), providing strong confidence to proceed to human trials.